American CryoStem Corp. is engaged in the development, market, and licenses patented adipose tissue-based cellular technologies, bio-materials, and related proprietary services. The company is headquartered in Eatontown, New Jersey and currently employs 6 full-time employees. The company went IPO on 2010-10-02. The firm has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The firm has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Company’s ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured using patented cell culture media for growing human stromal cells. The firm also includes ATGRAFT services.

Industry: Services-Misc Health & Allied Services, NEC Peers: Bone Biologics Corp Protagenic Therapeutics Inc NeuBase Therapeutics, Inc. Ernexa Therapeutics Inc Skye Bioscience Inc Aixcrypto Holdings Inc Transcode Therapeutics Inc